Parte, Capitolo, Paragrafo

 1 Intro, 0,0(1)|                  R., Orians C., Ascher N., The potential supply of organ
 2 Intro, 0,0(1)|                   donors; an assessment of the efficacy of organ procurement
 3 Intro, 0,0(1)|               organ procurement efforts in the United States. JAMA 1992;
 4 I, 1,1(5)    |                 eds. Xeno-transplantation. The Transplantation of Organs
 5 I, 1,1(7)    |    xenotransplantation – A brief review of the world experience. In: Taniguchi
 6 I, 1,1(7)    |                 eds. Xeno-transplantation. The Transplantation of Organs
 7 I, 1,1(9)    |                   y., rolf j.l.l., et al., The Pig as Potential Organ Donor
 8 I, 1,1(9)    |                 eds. Xeno-transplantation. The Transplantation of Organs
 9 I, 1,1(10)   |            transgenic pig model system for the study of discordant xenotransplantation,
10 I, 1,1(10)   |                  B.C., Byrne G.W., et al., The role of antibodies in acute
11 I, 2,2(14)   |                   complement activation in the hyperacute rejection of
12 I, 2,2(16)   |              cardiac xenograft survival in the baboon, J. Heart. Transplant.
13 I, 2,2(16)   |              Bjorck S., et al., Studies on the removal of anti-pig xenoantibodies
14 I, 2,2(16)   |                 anti-pig xenoantibodies in the human by plasmapheresis/
15 I, 2,2(17)   |                Finstad J., et al., Role of the complement system in graft
16 I, 2,2(17)   |                    Bollinger R.R., et al., The effect of soluble complement
17 I, 2,2(17)   |                    FUT-175 and K76COOH, in the prevention of hyperacute
18 I, 2,2(19)   |            transgenic pig model system for the study of discordant xenotransplantation,
19 I, 2,2(19)   |                    Cozzi E., White D.J.G., The generation of transgenic
20 I, 2,2(19)   |              transgenic pig as a model for the prevention of xenogeneic
21 I, 2,2(20)   |                    Enzymatic remodeling of the carbohydrate surface of
22 I, 2,3(31)   |         Accommodated xenografts survive in the presence of anti-donor antibodies
23 I, 2,3(34)   |               decay-accelerating factor on the inhibition of hyperacute
24 I, 2,3(34)   |                 eds. Xeno-transplantation. The Transplantation of Organs
25 I, 2,4(39)   |                     et al., An approach to the control of disease transmission
26 I, 2,4(41)   |               endogenous retroviruses, and the evolution of retroelements,
27 I, 2,4(43)   |             Chapman L, Lockey C, Onions D, The XEN111 Study group, et al,
28 I, 3,6(48)   |                   Functional evaluation of the AMC-BAL to be employed in
29 I, 3,6(49)   |                Brink J., et al., Report of the xenotransplantation advisory
30 I, 3,6(49)   |  xenotransplantation advisory committee of the international society for
31 I, 3,6(49)   |                  and lung transplantation. The present status of xenotransplantation
32 I, 3,6(49)   |                  and its potential role in the treatment of end-stage cardiac
33 II, 1,8(57)  |                 Pimlico, London; Regan T., The case for Animal Rights,
34 II, 2,12(65) |                   24:722-727; Hanson M.J., The Seductive Sirens of Medical
35 II, 2,12(65) |                Sirens of Medical Progress. The case of Xenotransplantation,
36 II, 2,12(65) |               Animal-to-Human Transplants: the Ethics of Xenotransplantation,
37 II, 2,12(65) |               Trials with Xenotransplants, The Lancet, 1998, 351: 1347-
38 II, 2,12(65) |               Little Piggy Went to Market: The Xenotransplantation and
39 II, 2,12(65) |                    K.C., Lanza R.P., Xeno, the Promise of Transplanting
40 II, 2,12(65) |                 clinical issues concerning the use of Xenotransplantation
41 II, 2,13(67) |                   K., Xenotransplantation: The Challenge to Current Psychological
42 II, 2,14(68) |        Xenotransplantation. Reflections on the Ethics of the Early Phase,
43 II, 2,14(68) |               Reflections on the Ethics of the Early Phase, J Med Ethics
44 II, 2,16(71) |              persons, informed consent and the assessment of infectious
45 II, 2,17(72) |               Urruela Mora A., Workshop on the ethical, sociologic, economic
46 II, 3,21(75) |                   orientamenti in materia: the Council of Europe, the Health
47 II, 3,21(75) |                     the Council of Europe, the Health Council of the Netherlands,
48 II, 3,21(75) |              Europe, the Health Council of the Netherlands, the Swedish
49 II, 3,21(75) |                Council of the Netherlands, the Swedish Committee on Xenotransplantation,
50 II, 3,21(75) |                    on Xenotransplantation, the Spanish Xenotransplantation
51 II, 3,21(75) |         Xenotransplantation Sub-committee, the Argentine National Commission
52 II, 3,21(75) |                    on Xenotransplantation, the US Department of Health
53 II, 3,21(75) |                    on Xenotransplantation, the United Kingdom Xenotransplantation
54 II, 3,21(75) |                  Regulatory Authority, and the Italian Xenotransplantation
55 II, 3,21(75) | Xenotransplantation Commission. In France, the ethical aspects are currently
56 II, 3,21(75) |                currently being examined by the French National Ethics Committee
57 II, 3,21(75) |                  clinical trials will need the approval of the newly formed
58 II, 3,21(75) |                  will need the approval of the newly formed Agency for
59 II, 3,21(75) |                    newly formed Agency for the Security of Health Products
60 II, 3,21(75) |                  of Health Products and of the Ministry of Health. In Germany,
61 II, 3,21(75) |            Ministry of Health. In Germany, the German Medical Council has
62 II, 3,21(75) |                 Canada 'Health Canada' has the authority to regulate xenotransplantation